RIGL
HealthcareRigel Pharmaceuticals, Inc. · Biotechnology · $840M
What is Rigel Pharmaceuticals, Inc.?
Rigel Pharmaceuticals is a South San Francisco-based biotechnology company focused on discovering and developing small molecule drugs for hematologic disorders, rare immune diseases, and cancer. Founded in 2000, the company has advanced from early-stage research to a commercial-stage operation with an approved therapy on the market.
Rigel generates revenue primarily through its approved oral therapy Tavalisse, which targets chronic immune thrombocytopenia in adult patients. Beyond its commercial product, the company advances a pipeline of small molecule candidates across phase I and phase III clinical trials targeting autoimmune, inflammatory, and hematology-oncology indications. Rigel also monetizes its research through licensing and collaboration agreements with global pharmaceutical partners including AstraZeneca, Eli Lilly, Daiichi Sankyo, and Kissei Pharmaceutical.
Rigel Pharmaceuticals was founded in 2000 and is headquartered in South San Francisco, California.
- Tavalisse — approved oral SYK inhibitor for chronic immune thrombocytopenia
- Fostamatinib — phase III candidate for warm autoimmune hemolytic anemia
- R289 — oral IRAK 1/4 inhibitor in phase I for autoimmune and hematology-oncology diseases
- R552 — RIPK1 inhibitor with completed phase I data in autoimmune conditions
- Licensing collaborations with AstraZeneca, Eli Lilly, Daiichi Sankyo, and Kissei
Is RIGL a Good Stock to Buy?
UQS Score rates RIGL as Very Good overall.
Rigel's strongest signals come from its Quality and Risk pillars, both rated Strong — reflecting a business profile that compares favorably to many small-cap biotech peers on financial discipline and balance sheet resilience. The Valuation pillar is rated Attractive, suggesting the market may not be fully pricing in the company's commercial and pipeline assets.
The Moat pillar is rated Weak, which is common for small biotechs that depend on a limited number of approved products and face ongoing competitive pressure from larger pharmaceutical companies.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RIGL pay dividends?
No — Rigel Pharmaceuticals, Inc. does not currently pay a dividend.
Rigel Pharmaceuticals does not currently pay a dividend. This is typical for clinical-stage and early commercial biotechnology companies, where available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in RIGL are generally seeking growth from pipeline milestones and commercial expansion rather than income.
When does RIGL report earnings?
Rigel Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed public companies.
Quarterly results for Rigel typically reflect Tavalisse net product revenue alongside collaboration and licensing income. Pipeline progress, clinical trial updates, and operating expense trends are key items investors monitor each reporting period.
For the most recent quarter's results and upcoming reporting dates, visit Rigel Pharmaceuticals' investor relations page directly.
RIGL Price History
+9.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Rigel Pharmaceuticals, Inc.?
Based on Rigel Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RIGL Long-term Outlook
Rigel's Growth pillar is rated Neutral, reflecting a company in transition — it has an approved commercial product but remains dependent on pipeline catalysts for meaningful revenue expansion. The Strong Risk rating suggests the company is managing its operational and financial risks better than many small-cap biotech peers. Near-term trajectory will likely hinge on Fostamatinib trial readouts and the depth of Tavalisse commercial penetration, while licensing milestones from partners like Eli Lilly and AstraZeneca could provide additional upside.
Growth drivers
- Phase III readouts for Fostamatinib across multiple indications
- Continued Tavalisse commercial adoption in immune thrombocytopenia
- Milestone and royalty payments from global licensing partnerships
Key risks
- Clinical trial failure risk across multiple pipeline candidates
- Dependence on a single approved commercial product for near-term revenue
- Competitive pressure from larger, better-resourced pharmaceutical companies
RIGL vs Peers
Rigel operates in a competitive small-cap biotech space alongside several companies pursuing rare disease and specialty pharmaceutical programs.
Crescent Biopharma focuses on oncology-targeted therapies and differs from Rigel in its earlier-stage pipeline and narrower therapeutic focus.
Palatin Technologies concentrates on melanocortin receptor-targeted drugs, giving it a distinct mechanism of action compared to Rigel's kinase inhibitor platform.
Prothena targets neurodegenerative and rare diseases with a biologics-focused approach, contrasting with Rigel's small molecule drug strategy.
Frequently Asked Questions
What does Rigel Pharmaceuticals do?
Rigel Pharmaceuticals discovers and develops small molecule drugs targeting hematologic disorders, rare immune diseases, and cancer. Its approved product, Tavalisse, treats chronic immune thrombocytopenia in adults. The company also advances a clinical pipeline and generates revenue through licensing agreements with major pharmaceutical partners globally.
Does RIGL pay dividends?
Rigel Pharmaceuticals does not pay a dividend. Like most small-cap biotechnology companies, Rigel reinvests its capital into research, clinical development, and commercialization activities rather than returning cash to shareholders through distributions.
When does RIGL report earnings?
Rigel reports financial results on a quarterly basis, in line with standard US public company requirements. For exact upcoming reporting dates, check Rigel Pharmaceuticals' investor relations page, as our data source does not carry forward-looking earnings calendar dates.
Is RIGL a good stock to buy?
UQS Score rates RIGL as Very Good overall, with Strong ratings in Quality and Risk, and an Attractive Valuation signal. The Moat pillar is rated Weak, which is a common characteristic among small-cap biotechs. The full pillar breakdown is available to UQS Pro members.
Is RIGL overvalued?
The UQS Valuation pillar for RIGL is rated Attractive, suggesting the stock may be reasonably priced relative to its fundamentals when compared to sector peers. Valuation in biotech is inherently tied to pipeline risk, so investors should weigh this signal alongside the Risk and Growth pillar ratings.
How does RIGL compare to its competitors?
Rigel stands out among small-cap biotech peers by having an approved commercial product — Tavalisse — alongside an active clinical pipeline and multiple licensing partnerships. Competitors like Palatin Technologies and Prothena pursue different therapeutic mechanisms, while Crescent Biopharma focuses more narrowly on oncology at an earlier development stage.
What is RIGL's market cap bracket?
Rigel Pharmaceuticals is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and risk than mid- or large-cap peers, but may also offer greater upside potential tied to clinical and commercial milestones.
Who founded Rigel Pharmaceuticals?
Rigel Pharmaceuticals was founded in 2000. Details on the founding team are widely available through the company's official history and public filings on its investor relations website.
Is RIGL a long-term quality investment?
From a quality indicator perspective, RIGL's Strong Quality and Risk pillar ratings suggest the company demonstrates above-average financial discipline for its peer group. Long-term outcomes in biotech depend heavily on pipeline success and commercial execution — the UQS composite provides a structured framework for evaluating these dimensions over time.
What is the main competitive advantage of Rigel Pharmaceuticals?
Rigel's platform centers on small molecule kinase inhibitors, a technically demanding area where the company has built meaningful expertise. Its approved product provides a commercial foundation, while licensing agreements with large partners like Eli Lilly and AstraZeneca validate the scientific approach and provide non-dilutive capital.
What sector does RIGL belong to?
Rigel Pharmaceuticals operates in the Healthcare sector, specifically within biotechnology. The company focuses on rare hematologic and immune diseases — a specialty area that often attracts premium valuations when clinical programs succeed, but carries significant binary risk around trial outcomes.
Is RIGL a growth stock or value stock?
Based on UQS pillar ratings, RIGL shows a Neutral Growth signal and an Attractive Valuation signal — a combination that positions it closer to a value-oriented biotech than a high-growth momentum name. Investors seeking pipeline-driven upside at a reasonable entry point may find this profile worth examining further.
Unlock Full RIGL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare RIGL against sector peers on quality signals
- ✓Track Risk and Valuation changes over time
- ✓Get the full analyst-grade view in one dashboard
Pro Analysis
RIGL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | 14.3 | 0.0 | 35.0 | 0.0 | 36.9 | 0.0 | -46.1 |
| Aug 7, 2026 | 60.4 | 60.0 | 35.0 | 64.3 | 58.8 | 100.0 | -9.6 |
| Aug 3, 2026 | 70.0 | 100.0 | 35.0 | 64.3 | 87.9 | 99.8 | 0.0 |
| Aug 1, 2026 | 70.0 | 100.0 | 35.0 | 64.3 | 87.9 | 99.6 | 0.0 |
| Jul 29, 2026 | 70.0 | 100.0 | 35.0 | 61.7 | 87.9 | 99.2 | 0.0 |
| Jul 25, 2026 | 70.0 | 100.0 | 35.0 | 61.7 | 87.9 | 99.7 | 0.0 |
| Jul 24, 2026 | 70.0 | 100.0 | 35.0 | 61.7 | 87.9 | 99.6 | 0.0 |
| Jul 23, 2026 | 70.0 | 100.0 | 35.0 | 61.7 | 87.9 | 99.4 | 0.0 |
| Jul 22, 2026 | 70.0 | 100.0 | 35.0 | 61.7 | 87.9 | 99.1 | 0.0 |
| Jul 21, 2026 | 70.0 | 100.0 | 35.0 | 61.7 | 87.9 | 98.8 | 0.0 |
RIGL — Pillar Breakdown
Quality
— 0.0/100 (25%)Rigel Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Rigel Pharmaceuticals, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)Rigel Pharmaceuticals, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Rigel Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 35/100 (25%)Rigel Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RIGL.
Score Composition
Financial Data
More Stock Analysis
How is the RIGL UQS Score Calculated?
The UQS (Unified Quality Score) for Rigel Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Rigel Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Rigel Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.